Thermo Fisher Scientific Inc. in 3 stories
The narratives TMO currently appears in, with its side and exposure in each.
Bull side
3 stories- GLP-1 Eats Everything
TMO in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
The proliferation of obesity-drug programs supports demand for Thermo Fisher's clinical-trial, bioprocessing and contract-manufacturing services.
- Drug Manufacturing De-Risks From China
TMO in “Drug Manufacturing De-Risks From China”
FadingExposure: not rated yetWestern drugmakers are paying for non-Chinese capacity before procurement restrictions become binding.
Its Patheon network and life-science tools portfolio benefit from duplicated supply chains and new Western capacity.
- The Patent Cliff Sparks a Biotech Land Grab
TMO in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Thermo Fisher earns from research tools, clinical services and manufacturing regardless of which external drug candidates win.
Bear side
0 storiesNo bear-side stories for TMO yet.